Navigation Links
GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch'
Date:10/25/2010

LILLE, France and CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it has been selected by Windhover as one of the "Top Biopharma Projects To Watch" in 2011 in the cardiovascular/metabolic category. This announcement is part of the conference event organized by Elsevier Business Intelligence and Windhover Conferences taking place in Boston from November 2-4, 2010, where GENFIT will be presenting its latest scientific achievements.

"This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, vice president, content, for Elsevier Business Intelligence's publications. "Many of our past winners have gone on to do big deals, and we expect the same from this year's companies."

The Windhover conference annually elects 10 biopharmaceutical companies with high-value assets for partnership in six specific therapeutic areas: cardiovascular/metabolic, oncology, neuroscience, infectious diseases, inflammatory/autoimmune and a category including ophthalmology, orphan diseases, and women's health. 

Dr. Dean W. Hum, chief scientific officer of GENFIT, added,"Being a well recognized company in the U.S. in our specific therapeutic area is a great honor for us. We will present our most advanced drug candidate in the field of diabetes, GFT505, and our specific and innovative approach to the prevention and treatment of cardiometabolic diseases. This will be illustrated by the presentation of other internal research programs, in particular those dedicated to the discovery of early biomarkers and those dealing with the connection between circadian cycle dysregulation and metabolic diseases."

About Windhover:Windhover Information Inc, an Elsevier company, has
'/>"/>

SOURCE GENFIT
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
5. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
8. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
(Date:12/17/2014)... Germany , December 17, 2014 ... level of expenditure on research and development In ... increased its revenue by two percent to EUR 4.287 billion ... (EBIT) grew by 14 percent to EUR 360 million. "Overall, ... said Dr. Michael Kaschke , President and CEO of ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... SAN DIEGO, May 18, 2012  Ocera Therapeutics Inc., ... and commercialization of proprietary agents to treat gastrointestinal ... received a CE Mark for Zysa™ (spherical carbon ... predominant IBS (IBS-d), a condition affecting 10-15% of ...
... May 18, 2012  Actavis Group, an international generic ... FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, ... GlaxoSmithKline,s Requip® XL.  Actavis believes this is the ... Distribution of the product has commenced.   ...
Cached Medicine Technology:Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 3Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets) 2
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... that allege a metal-on-metal version of the artificial ... forward in state and federal courts, Bernstein Liebhard ... New Jersey’ Bergen County Superior Court on December ... permitted to begin deposition of plaintiffs on November ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer ... dress fans. The company has recently updated its official ... the holiday season, Angeldress Blog has recommended ... , Angeldress.co.uk prides itself in offering a huge selection ... All the company’s outfits are very carefully selected based ...
(Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress company ... dress promotion. All the old and new customers can ... Balfleet.com is well-known for its high quality trendy women’s ... dresses and more. Its formal dresses are quality made ... can create an elegant look when paired with any ...
(Date:12/19/2014)... 2014 The Plantrician Project ... educational events, tools and resources for healthcare professionals ... , the world’s leading online cooking school, have ... being needs: Culinary Rx. As an online food ... Rx, scheduled for debut spring 2015, will be ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4
... disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay News) ... pressure (CPAP) to treat people with obstructive sleep apnea ... the arteries -- within months, a new study finds. ... a direct link between obstructive sleep apnea and atherosclerosis, ...
... Calif., Oct. 12 Yesterday,Governor Schwarzenegger signed into ... to service and extend benefits to children and ... permanency. One important bill in this,package of legislation ... the current system of group home care into ...
... 12 The Agency for,Healthcare Research and Quality, part ... today the award of $41.6 million over the next ... centers as part of its,Centers for Education and Research ... the CERTs program. "Expanding the Centers for Education ...
... Shown to Prevent Post-Meal Oxidative Stress, FRESNO, Calif., ... It is probably a good idea based on health ... Health Effects of,Fruits and Vegetables in Houston, Texas this ... foods should be,consumed with each meal to prevent periods ...
... with the confusion of ... to their children, CINCINNATI, Oct. 12 All too ... give our children, especially,when it comes to the readily available ... as a frightening, but,important reminder that no medicine comes without ...
... Prior to Stroke, CLEVELAND, Oct. 12 Carotid ... today, are a significant risk factor,for stroke but many ... ultrasound screening is a successful tool for revealing,blocked carotid ... before death or,disability occurs. Life Line Screening, the ...
Cached Medicine News:Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 3Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 2Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 3Health News:Grape Consumption Improves Antioxidant Capacity in Humans 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 3Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 4Health News:Asymptomatic Carotid Artery Blockage a Significant Stroke Risk 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a scientifically advanced nutritional formulation that ... full body health. MacularProtect Complete-S, based ... other advanced research, delivers a diverse ... mg of FloraGLO® lutein and other ...
... PreserVision® Soft Gel Lutein patented formula is ... Lomb PreserVision® AREDS formula, with the beta-carotene ... Lutein is a carotenoid found in dark ... is highly concentrated in the macula, the ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: